Clinical momentum Stelexis has demonstrated positive Phase 1 results for eganelisib in relapsed/refractory AML and higher-risk MDS, presented at ASCO 2026, indicating a potential near-term need for collaboration on translational research, biomarker services, or companion diagnostics to support ongoing trials and future commercialization.

Funding & scale With a Series A of 43 million and a revenue range of 10 to 25 million, Stelexis shows funding adequacy to pursue preclinical-to-clinical development and may require CRO partnerships, regulated manufacturing, or analytical instrumentation to scale up research and clinical-grade workflows.

Strategic focus As a Deerfield-founded, New York-based cancer therapeutics company focused on interception-based cancer strategies, there is a potential opportunity to offer platform-enabling technologies, data analytics, bioinformatics, and partnerships that accelerate target discovery and early development.

Clinical development needs Recent ASCO activity suggests ongoing clinical development; potential sales angles include clinical trial supply services, biomarker assay development, companion diagnostic integration, and specialized imaging or analytics to support trial endpoints and decision-making.

Industry positioning Operating in a competitive biotechnology landscape with peers of substantial scale, Stelexis may benefit from partnerships on manufacturing scalability, regulatory affairs support, and pharmacovigilance capabilities to de-risk later-stage trials and prepare for potential licensing or acquisition discussions.